Codexis Company Profile (NASDAQ:CDXS)

About Codexis (NASDAQ:CDXS)

Codexis logoCodexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Industry, Sector and Symbol:
  • Sector: Industrial Products
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CDXS
  • CUSIP: 19200510
  • Web:
  • Market Cap: $285.11 million
  • Outstanding Shares: 48,324,000
Average Prices:
  • 50 Day Moving Avg: $5.42
  • 200 Day Moving Avg: $4.92
  • 52 Week Range: $3.60 - $5.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -48.75
  • P/E Growth: -1.02
Sales & Book Value:
  • Annual Revenue: $43.16 million
  • Price / Sales: 6.55
  • Book Value: $0.63 per share
  • Price / Book: 9.29
  • EBIDTA: ($15,160,000.00)
  • Net Margins: -40.70%
  • Return on Equity: -83.39%
  • Return on Assets: -45.44%
  • Current Ratio: 3.06%
  • Quick Ratio: 2.99%
  • Average Volume: 146,027 shs.
  • Beta: -1.37
  • Short Ratio: 14.32

Frequently Asked Questions for Codexis (NASDAQ:CDXS)

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.13). The company had revenue of $10.30 million for the quarter, compared to analyst estimates of $9.61 million. Codexis had a negative net margin of 40.70% and a negative return on equity of 83.39%. The firm's revenue was down 35.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 earnings per share. View Codexis' Earnings History.

When will Codexis make its next earnings announcement?

Codexis is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Codexis.

Where is Codexis' stock going? Where will Codexis' stock price be in 2017?

4 equities research analysts have issued 12-month price objectives for Codexis' stock. Their forecasts range from $5.50 to $8.00. On average, they anticipate Codexis' share price to reach $6.94 in the next twelve months. View Analyst Ratings for Codexis.

Who are some of Codexis' key competitors?

Who are Codexis' key executives?

Codexis' management team includes the folowing people:

  • Bernard J. Kelley, Chairman of the Board
  • John J. Nicols, President, Chief Executive Officer, Director
  • Gordon T. Sangster, Chief Financial Officer, Senior Vice President
  • Douglas T. Sheehy J.D., Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
  • Michael Douglas Arthur Aldridge, Senior Vice President - Corporate & Strategic Development
  • James Lalonde, Senior Vice President, Research & Development
  • Thomas R. Baruch J.D., Chairman Emeritus
  • Pam P. Cheng, Director
  • Kathleen Sereda Glaub, Director
  • Patrick Y. Yang, Director

Who owns Codexis stock?

Codexis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vivo Capital LLC (10.99%), Prescott Group Capital Management L.L.C. (4.24%), Vanguard Group Inc. (3.67%), Baillie Gifford & Co. (3.03%), FMR LLC (2.56%) and William Blair Investment Management LLC (2.26%). Company insiders that own Codexis stock include Bernard J Kelley, Dennis P Wolf, James Lalonde, Patrick Y Yang, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.

Who sold Codexis stock? Who is selling Codexis stock?

Codexis' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, FMR LLC, Arrowstreet Capital Limited Partnership and New York State Common Retirement Fund. View Insider Buying and Selling for Codexis.

Who bought Codexis stock? Who is buying Codexis stock?

Codexis' stock was acquired by a variety of institutional investors in the last quarter, including Prescott Group Capital Management L.L.C., Vanguard Group Inc., Baillie Gifford & Co., First Light Asset Management LLC, State Street Corp, Blair William & Co. IL, William Blair Investment Management LLC and Northern Trust Corp. View Insider Buying and Selling for Codexis.

How do I buy Codexis stock?

Shares of Codexis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Codexis' stock price today?

One share of Codexis stock can currently be purchased for approximately $5.85.

MarketBeat Community Rating for Codexis (NASDAQ CDXS)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Codexis (NASDAQ:CDXS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $6.94 (18.59% upside)

Analysts' Ratings History for Codexis (NASDAQ:CDXS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017HC WainwrightSet Price TargetBuy$8.00HighView Rating Details
5/31/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$8.00HighView Rating Details
1/26/2017First AnalysisDowngradeOverweight -> Equal Weight$5.50N/AView Rating Details
1/4/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> Buy$6.25N/AView Rating Details
(Data available from 9/19/2015 forward)


Earnings History for Codexis (NASDAQ:CDXS)
Earnings by Quarter for Codexis (NASDAQ:CDXS)
Earnings History by Quarter for Codexis (NASDAQ CDXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.17)N/AView Earnings Details
8/9/2017Q2 2017($0.13)($0.13)$9.61 million$10.30 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.15)($0.18)$9.23 million$7.97 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.11)($0.12)$9.15 million$10.00 millionViewListenView Earnings Details
11/8/2016Q3($0.14)$0.06$7.41 million$14.90 millionViewListenView Earnings Details
8/9/2016Q216$0.03$0.12$15.10 million$16.00 millionViewListenView Earnings Details
5/9/2016Q1($0.15)($0.11)$7.49 million$8.00 millionViewListenView Earnings Details
3/3/2016Q4($0.04)$0.02$11.63 million$11.60 millionViewN/AView Earnings Details
11/4/2015Q315($0.11)$0.13$8.85 million$17.40 millionViewListenView Earnings Details
8/11/2015Q215($0.14)($0.14)$7.34 million$6.02 millionViewListenView Earnings Details
5/7/2015Q115($0.12)($0.14)$8.00 million$6.80 millionViewListenView Earnings Details
3/3/2015Q414$0.01$0.07$13.30 million$14.20 millionViewListenView Earnings Details
11/4/2014Q314($0.06)($0.05)$9.00 million$7.47 millionViewListenView Earnings Details
8/6/2014Q214($0.15)($0.22)$8.50 million$6.60 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.17)$10.00 million$7.10 millionViewListenView Earnings Details
3/11/2014Q413($0.21)($0.26)$10.00 million$9.50 millionViewListenView Earnings Details
11/12/2013Q313($0.31)($0.24)$8.50 million$3.90 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.28)($0.33)$9.00 million$6.97 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.36)($0.25)$7.63 million$11.48 millionViewListenView Earnings Details
2/27/2013Q4 2012($0.34)($0.41)$9.33 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.15)($0.06)$25.88 million$26.34 millionViewN/AView Earnings Details
8/9/2012($0.18)($0.15)ViewN/AView Earnings Details
5/10/2012($0.15)($0.21)ViewN/AView Earnings Details
2/7/2012($0.11)($0.15)ViewN/AView Earnings Details
11/1/2011($0.08)($0.08)ViewN/AView Earnings Details
7/28/2011($0.10)($0.14)ViewN/AView Earnings Details
5/5/2011($0.07)($0.10)ViewN/AView Earnings Details
2/3/2011($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Codexis (NASDAQ:CDXS)
2017 EPS Consensus Estimate: ($0.32)
2018 EPS Consensus Estimate: ($0.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20172($0.14)($0.12)($0.13)
Q3 20172($0.17)($0.14)($0.16)
Q4 20171$0.07$0.07$0.07
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.07)($0.07)($0.07)
Q4 20181$0.20$0.20$0.20
(Data provided by Zacks Investment Research)


Dividend History for Codexis (NASDAQ:CDXS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Codexis (NASDAQ:CDXS)
Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 63.62%
Insider Trades by Quarter for Codexis (NASDAQ:CDXS)
Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)
Insider Trades by Quarter for Codexis (NASDAQ:CDXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017Ventures Vii Affiliates F VivoMajor ShareholderSell1,060,000$5.78$6,126,800.00View SEC Filing  
11/15/2016Patrick Y YangDirectorBuy10,000$4.83$48,300.00View SEC Filing  
9/8/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell111,600$4.25$474,300.00View SEC Filing  
8/29/2016Dennis P WolfDirectorSell18,000$4.22$75,960.00View SEC Filing  
8/24/2016Bernard J KelleyDirectorSell12,643$4.26$53,859.18View SEC Filing  
8/16/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell86,894$4.25$369,299.50View SEC Filing  
8/15/2016Vivo Ventures Vii, LlcMajor ShareholderSell50,000$4.27$213,500.00View SEC Filing  
8/4/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell80,000$4.22$337,600.00View SEC Filing  
11/11/2015James LalondeSVPSell9,441$3.52$33,232.32View SEC Filing  
9/11/2015Patrick Y YangDirectorBuy10,000$3.47$34,700.00View SEC Filing  
9/10/2015Bernard J. KelleyDirectorSell5,200$3.45$17,940.00View SEC Filing  
8/24/2015Patrick Y YangDirectorBuy10,000$3.84$38,400.00View SEC Filing  
8/14/2015Patrick Y YangDirectorBuy20,000$3.97$79,400.00View SEC Filing  
6/15/2015Dennis P WolfDirectorSell35,416$4.10$145,205.60View SEC Filing  
11/18/2014Patrick Y YangDirectorBuy20,000$2.35$47,000.00View SEC Filing  
11/17/2014Patrick Y YangDirectorBuy20,000$2.34$46,800.00View SEC Filing  
8/12/2014Patrick Y YangDirectorBuy60,000$2.22$133,200.00View SEC Filing  
3/8/2013John J NicolsCEOBuy27,000$2.42$65,340.00View SEC Filing  
3/7/2013John J NicolsCEOBuy54,000$2.22$119,880.00View SEC Filing  
3/4/2013David D O'tooleCFOBuy10,000$2.02$20,200.00View SEC Filing  
11/12/2012David D O'tooleCFOBuy5,000$2.20$11,000.00View SEC Filing  
9/14/2012David D O'tooleCFOBuy5,000$2.78$13,900.00View SEC Filing  
9/14/2012Douglas T SheehySVPSell3,800$2.76$10,488.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Codexis (NASDAQ:CDXS)
Latest Headlines for Codexis (NASDAQ:CDXS)
DateHeadline logoCodexis, Inc. (CDXS) Major Shareholder Ventures Vii Affiliates F. Vivo Sells 1,060,000 Shares - September 18 at 10:26 PM logoComparing Codexis (CDXS) and Its Rivals - September 17 at 10:32 PM logo$10.00 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter - September 10 at 5:40 AM logoCodexis (CDXS) Presents At 24th Annual NewsMakers In The Biotech Industry - Slideshow - September 9 at 9:44 PM logo-$0.14 Earnings Per Share Expected for Codexis, Inc. (CDXS) This Quarter - September 8 at 2:20 PM logoCodexis, Inc. (CDXS) Given Consensus Rating of "Hold" by Brokerages - September 6 at 2:28 AM logoCodexis, Inc. (CDXS) Downgraded to "Sell" at Zacks Investment Research - September 4 at 6:22 PM logoCodexis, Inc. (CDXS) Upgraded to Hold by ValuEngine - September 3 at 7:08 PM logoCodexis to Present at Four Investment Conferences in September - August 31 at 4:58 PM logoCodexis, Inc. (CDXS) Upgraded at BidaskClub - August 19 at 7:46 PM logo3 Stocks Set to Pop - August 16 at 2:24 PM logoFinancial Comparison: Codexis (NASDAQ:CDXS) & Repros Therapeutics (RPRX) - August 14 at 8:06 PM logoCodexis, Inc. (NASDAQ:CDXS) Rating Lowered to Hold at Zacks Investment Research - August 14 at 6:38 PM logoQ3 2017 EPS Estimates for Codexis, Inc. (NASDAQ:CDXS) Lowered by Jefferies Group - August 14 at 3:34 AM logoHC Wainwright Analysts Give Codexis, Inc. (NASDAQ:CDXS) a $8.00 Price Target - August 13 at 3:32 PM logoCodexis, Inc. (NASDAQ:CDXS) Receives Consensus Recommendation of "Hold" from Brokerages - August 12 at 2:32 AM logoJefferies Group Brokers Reduce Earnings Estimates for Codexis, Inc. (CDXS) - August 11 at 1:22 PM logoEdited Transcript of CDXS earnings conference call or presentation 9-Aug-17 8:30pm GMT - August 10 at 6:17 PM logoCodexis, Inc. (CDXS) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - August 9 at 11:16 PM logoCodexis reports 2Q loss - August 9 at 10:18 PM logoCodexis Reports Financial Results for the Second Quarter of 2017 - August 9 at 5:14 PM logoCodexis (CDXS) Says Court Ordered Summary Judgment of Patent Infringement against EnzymeWorks - August 9 at 2:53 AM logoCodexis Obtains Court Order Awarding Summary Judgment of Patent Infringement against EnzymeWorks - August 8 at 4:47 PM logoZacks: Brokerages Expect Codexis, Inc. (NASDAQ:CDXS) Will Post Quarterly Sales of $10.04 Million - August 4 at 7:45 AM logoZacks: Analysts Expect Codexis, Inc. (CDXS) to Announce -$0.13 Earnings Per Share - August 2 at 6:23 PM logoCodexis to Hold 2017 Second Quarter Conference Call on August 9 - August 2 at 8:21 AM logoBidaskClub Downgrades Codexis, Inc. (NASDAQ:CDXS) to Hold - July 29 at 7:56 PM logoCodexis, Inc. (CDXS) Upgraded by Zacks Investment Research to "Buy" - July 19 at 8:34 PM logoCodexis, Inc. (NASDAQ:CDXS) Receives Consensus Rating of "Hold" from Brokerages - July 18 at 1:45 PM logo$10.04 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter - July 13 at 11:04 AM logoCodexis, Inc. (CDXS) Stock Rating Upgraded by Zacks Investment Research - July 11 at 6:40 PM logoETFs with exposure to Codexis, Inc. : July 11, 2017 - July 11 at 6:04 PM logo Analysts Anticipate Codexis, Inc. (CDXS) Will Post Earnings of -$0.13 Per Share - July 11 at 12:22 PM logoCodexis, Inc. (NASDAQ:CDXS) Downgraded by ValuEngine to Sell - July 9 at 12:02 AM logoETFs with exposure to Codexis, Inc. : June 26, 2017 - June 26 at 4:54 PM logoCodexis, Inc. (CDXS) Stock Rating Upgraded by ValuEngine - June 21 at 10:38 PM logoCodexis, Inc. (CDXS) Given Consensus Recommendation of "Hold" by Brokerages - June 21 at 4:42 PM logo Analysts Anticipate Codexis, Inc. (CDXS) Will Post Quarterly Sales of $10.04 Million - June 17 at 9:50 AM logoETFs with exposure to Codexis, Inc. : June 16, 2017 - June 16 at 4:58 PM logoCodexis, Inc. :CDXS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 15, 2017 - June 15 at 5:59 PM logo-$0.13 Earnings Per Share Expected for Codexis, Inc. (CDXS) This Quarter - June 15 at 10:50 AM logoCodexis, Inc. (CDXS) Forecasted to Earn Q2 2017 Earnings of ($0.14) Per Share - June 2 at 7:18 AM logoCodexis, Inc. (CDXS) Coverage Initiated at Jefferies Group LLC - May 31 at 7:38 AM logoCodexis to Present at Two Upcoming Investment Conferences - May 30 at 12:07 PM logoZacks Investment Research Lowers Codexis, Inc. (CDXS) to Sell - May 23 at 6:16 PM logoHC Wainwright Analysts Give Codexis, Inc. (CDXS) a $8.00 Price Target - May 13 at 6:58 PM logoEdited Transcript of CDXS earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 8:28 AM logoCodexis, Inc. (CDXS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS - May 9 at 9:22 PM logoCodexis reports 1Q loss - May 9 at 7:04 PM logoInvestor Network: Codexis, Inc. to Host Earnings Call - May 9 at 4:12 PM



Codexis (CDXS) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff